Sunshine Biopharma (SBFM) Equity Average (2016 - 2025)
Sunshine Biopharma (SBFM) has disclosed Equity Average for 11 consecutive years, with $24.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average rose 2.79% year-over-year to $24.9 million, compared with a TTM value of $24.9 million through Sep 2025, up 2.79%, and an annual FY2024 reading of $22.4 million, up 4.37% over the prior year.
- Equity Average was $24.9 million for Q3 2025 at Sunshine Biopharma, up from $24.2 million in the prior quarter.
- Across five years, Equity Average topped out at $41.1 million in Q3 2022 and bottomed at -$1.0 million in Q3 2021.
- Average Equity Average over 5 years is $18.8 million, with a median of $23.0 million recorded in 2024.
- The sharpest move saw Equity Average tumbled 80.78% in 2021, then skyrocketed 6544.31% in 2022.
- Year by year, Equity Average stood at -$481135.0 in 2021, then surged by 6544.31% to $31.0 million in 2022, then plummeted by 30.38% to $21.6 million in 2023, then rose by 12.44% to $24.3 million in 2024, then rose by 2.77% to $24.9 million in 2025.
- Business Quant data shows Equity Average for SBFM at $24.9 million in Q3 2025, $24.2 million in Q2 2025, and $23.1 million in Q1 2025.